We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target ...
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
1d
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback